Table 2 The effect of magnesium and vitamin E co-supplementation on metabolic status in women with gestational diabetes
Variables | Placebo group (n = 30) | Magnesium plus vitamin E group (n = 30) | Difference in outcome measures between intervention and placebo treatment groups1 | |||
|---|---|---|---|---|---|---|
Baseline | Week 6 | Baseline | Week 6 | β (95% CI) | P2 | |
Magnesium (mg/dL) | 2.07 ± 0.15 | 2.02 ± 0.15 | 2.04 ± 0.22 | 2.18 ± 0.13 | 0.17 (0.11, 0.23) | < 0.001 |
FPG (mg/dL) | 91.9 ± 5.6 | 91.8 ± 6.4 | 90.3 ± 6.2 | 85.4 ± 5.9 | −5.20 (−7.88, −2.52) | 0.002 |
Insulin (μIU/mL) | 13.4 ± 4.1 | 14.9 ± 8.9 | 13.2 ± 3.6 | 11.5 ± 3.7 | −2.93 (−5.68, −0.18) | 0.02 |
HOMA-IR | 3.0 ± 0.9 | 3.3 ± 2.0 | 3.0 ± 0.8 | 2.4 ± 0.8 | −0.78 (−1.42, − 0.14) | 0.01 |
QUICKI | 0.32 ± 0.01 | 0.32 ± 0.02 | 0.32 ± 0.01 | 0.33 ± 0.02 | 0.01 (0.005, 0.02) | 0.002 |
Triglycerides (mg/dL) | 208.9 ± 52.1 | 54.2 | 206.3 ± 63.5 | 169.1 ± 65.9 | −50.31 (−67.58, −33.04) | < 0.001 |
VLDL-cholesterol (mg/dL) | 41.8 ± 10.4 | 44.5 ± 10.8 | 41.2 ± 12.7 | 33.8 ± 13.2 | −10.06 (−13.51, −6.60) | < 0.001 |
Total cholesterol (mg/dL) | 229.5 ± 41.2 | 232.9 ± 42.4 | 223.3 ± 49.0 | 201.3 ± 46.7 | −26.10 (−41.88, − 10.33) | 0.004 |
LDL-cholesterol (mg/dL) | 130.3 ± 36.4 | 131.6 ± 39.0 | 127.9 ± 41.7 | 113.4 ± 45.5 | −15.20 (−29.50, −0.91) | 0.03 |
HDL-cholesterol (mg/dL) | 57.4 ± 13.2 | 56.8 ± 11.3 | 54.1 ± 9.6 | 54.0 ± 8.7 | 0.70 (−3.07, 2.09) | 0.68 |
Total-/HDL-cholesterol ratio | 4.1 ± 1.0 | 4.2 ± 1.0 | 4.2 ± 0.8 | 3.8 ± 0.8 | −0.46 (−0.72, − 0.19) | < 0.001 |